Oxford center aims to increase clinical trial success rate

05/7/2013 | Bloomberg · PharmaTimes (U.K.)

A new research center at the University of Oxford aims to reduce the midstage clinical trial failure rate, which stands at about 90%. Hong Kong billionaire Li Ka-Shing and the U.K. government donated about $31 million each to fund the Li Ka-Shing Centre for Health Information and Discovery, with the goal of using data from patient records, genomic sequencing, clinical trials and national registries to help doctors make better decisions. Drugmakers Eli Lilly & Co., GlaxoSmithKline, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Novartis, AbbVie and Takeda are giving $8 million each to the Target Discovery Institute at Oxford in an effort to find innovative targets for drug development.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI